This week, Integra Therapeutics took part in an event to present the report HispanIA 2040: cómo la inteligencia artificial mejorará nuestro futuro (Spanish AI 2040: artificial intelligence for a better future) at the Ramón Areces Foundation in Madrid, with President of the Government of Spain Pedro Sánchez.
Also present at this event were Minister for Digital Transformation and Public Function Óscar López, Third Vice-President of the Government of Spain and Minister for Ecological Transition and Demographic Challenge Sara Aagesen, Minister for Home Affairs Fernando Grande-Marlaska, Minister for Transport and Sustainable Mobility Óscar Puente, and Minister for Agriculture, Fisheries and Food Luis Planas.
HispanIA 2040 is a strategic study promoted by the Spanish National Office of Foresight and Strategy, compiled by 12 experts from the public sector, academia and industry, including Dr Marc Güell, CSO and Co-Founder of Integra Therapeutics.
The Hispania 2040 study analyzes the opportunities and challenges of rolling out artificial intelligence (AI) to address the main challenges facing Spanish society in the long term: modernizing the private sector, strengthening the welfare state, achieving environmental sustainability, enhancing security and defense systems, and reducing inequality. Faced with these five challenges, the study proposes twelve priority lines of action.
Integra: AI for therapeutic tools
Integra Therapeutics was one of the three companies invited to share their experience applying AI for industrial purposes, specifically for designing new gene-editing tools. “Health is one of the areas where artificial intelligence can do the most. AI gives us a tool to not only read and write DNA, but also to start to speak to genetic code,” explained Dr Marc Güell.
Integra Therapeutics is a leading developer of gene and cell therapies to treat diseases that “currently have no cure,” explained Dr Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics. To do so, the company has developed the FiCAT platform, which can write therapeutic messages directly into the patient’s DNA.
“With AI we have been able to work with thousands of genome editor protein sequences and identify patterns that would be impossible to detect with the human eye. In the future, we should be able to recode genes to correct mutations and errors that cause devastating diseases,” added Sánchez-Mejías.
The Government has earmarked €1.5 billion for its 2024 Artificial Intelligence Strategy. On top of this, they announced yesterday that there will be an additional €150 million to promote AI in companies, with €20 million set aside for SMEs.
